Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information

Medical drugs

Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】

Telisotuzumab-EMRELIS medication precautions and safety and risk tips for long-term use

2026-02-01 22:25:32

Check Details

Possible reactions after discontinuation of tovorafenib and instructions for medication risks and safe discontinuation protocols

2026-02-01 22:25:32

Check Details

How long does it take for vorasidenib-VORANIGO to take effect and analysis of clinical course of treatment, onset of effect and patient experience

2026-02-01 22:25:32

Check Details

Zongatinib (Zongatinib) mechanism of action, pharmacological effects and scientific principles in tumor treatment

2026-02-01 22:25:32

Check Details

Is vosoritide effective for achondroplasia? Analysis of clinical efficacy and patient height improvement data

2026-02-01 22:25:32

Check Details

Methylcobalamin injection (Rozebalamin) latest price reference and application of medical insurance reimbursement policy

2026-02-01 22:25:32

Check Details

Real evaluation of the therapeutic effect of cobimetinib and long-term patient follow-up data

2026-02-01 22:25:32

Check Details

How much does a box of macitentan cost after it is included in medical insurance? List of policy implementation areas

2026-02-01 22:25:32

Check Details

Detailed explanation of the mechanism of action of Tilorisen (Harcos) and its impact on the central arousal system

2026-02-01 22:25:32

Check Details

Pretomanid’s mechanism of action, pharmacological characteristics and scientific analysis of multi-drug-resistant tuberculosis treatment

2026-02-01 22:25:32

Check Details

Tepotinib produces better response in adenocarcinoma versus non-adenocarcinoma MET exon 14 skipped non-small cell lung cancer

2026-02-01 22:25:32

Check Details

Zanzalintinib plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer without MSI-H or dMMR tumors

2026-02-01 22:25:32

Check Details

1
2
...
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439

Menu

Medical drugs

Telisotuzumab-EMRELIS medication precautions and safety and risk tips for long-term use

Possible reactions after discontinuation of tovorafenib and instructions for medication risks and safe discontinuation protocols

How long does it take for vorasidenib-VORANIGO to take effect and analysis of clinical course of treatment, onset of effect and patient experience

Zongatinib (Zongatinib) mechanism of action, pharmacological effects and scientific principles in tumor treatment

Is vosoritide effective for achondroplasia? Analysis of clinical efficacy and patient height improvement data

Methylcobalamin injection (Rozebalamin) latest price reference and application of medical insurance reimbursement policy

Real evaluation of the therapeutic effect of cobimetinib and long-term patient follow-up data

How much does a box of macitentan cost after it is included in medical insurance? List of policy implementation areas

Detailed explanation of the mechanism of action of Tilorisen (Harcos) and its impact on the central arousal system

Pretomanid’s mechanism of action, pharmacological characteristics and scientific analysis of multi-drug-resistant tuberculosis treatment

Tepotinib produces better response in adenocarcinoma versus non-adenocarcinoma MET exon 14 skipped non-small cell lung cancer

Zanzalintinib plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer without MSI-H or dMMR tumors

Category

相关知识